Complimentary approaches to metabolic syndrome: Opportunities and challenges

Pharmaceutical Regulatory Affairs: Open Access

ISSN: 2167-7689

Open Access

Complimentary approaches to metabolic syndrome: Opportunities and challenges

2nd International Conference and Exhibition on Pharmaceutical Regulatory Affairs

November 23-24, 2012 Hyderabad International Convention Centre, India

Ginpreet Kaur

Accepted Abstracts: Pharmaceut Reg Affairs

Abstract :

Metabolic syndrome has become a worldwide health problem as it affects more than one third of the population and it sets the stage for catastrophic health problems, such as hyperglycemia, high blood pressure, dyslipidaemia, heart disease, and other age-related diseases. But as a matter of fact, till date in modern medicine there has not been a single drug molecule to mitigate these interrelated states of multiple disorders. Although Diet, exercise, and nutritional supplementation play a key role in its prevention and treatment but it is difficult for patients to follow a diet/exercise regime that would improve their symptoms therefore natural products identified from traditional medicinal plants present an exciting opportunity for the treatment of metabolic syndrome because they contain a wide range of phytochemicals with diverse metabolic effects. We have discovered following plants which were found to be of significant importance such as Lagenaria siceraria with Trigonella foenum graecum for hyperlipidemia, Curcuma longa with piper nigrum and Allium cepa in the treatment of glucose tolerance associated with excess dietary fat intake, obesity and type 2 diabetes due to better safety, tolerability and increased healthcare costs with conventional pharmaceuticals. Globally,, with the advancement of modern medicine there has been a tremendous shift in expanding the horizons of availability of medications from traditional herbs as it has significant potential to deliver next generation medicines for metabolic syndrome with the ultimate goal of maximizing the opportunities and overcoming the challenges.

Biography :

Ginpreet Kaur has completed her M Pharm (Pharmacology) from Delhi Institute of Pharmaceutical Science and research (DIPSAR), Delhi University and PhD from SPP SPTM SVKM NMIMS University. She is the author and co-author of 16 research and review papers, including three book chapters. She is a member of several professional societies and is presently serving on the Editorial Boards of several scientific journals. Dr. Ginpreet is the recipient of Dr. Ashok B. Vaidya Prize? and Dr.R.D. Kulkarni Prize? for presenting paper in International Conference Organized by South Asian Chapter of American College of Clinical Pharmacology.

Google Scholar citation report
Citations: 499

Pharmaceutical Regulatory Affairs: Open Access received 499 citations as per Google Scholar report

Pharmaceutical Regulatory Affairs: Open Access peer review process verified at publons

Indexed In

arrow_upward arrow_upward